MYC-regulated pseudogene HMGA1P6 promotes ovarian cancer malignancy via augmenting the oncogenic HMGA1/2

[1]  A. Oza,et al.  Epithelial ovarian cancer: Evolution of management in the era of precision medicine , 2019, CA: a cancer journal for clinicians.

[2]  G. Mills,et al.  Advancing Drug Development in Gynecologic Malignancies , 2019, Clinical Cancer Research.

[3]  Wei Zhao,et al.  Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer , 2019, EBioMedicine.

[4]  A. Oza,et al.  Epithelial ovarian cancer , 2019, The Lancet.

[5]  Y. Mo,et al.  Role of Pseudogenes in Tumorigenesis , 2018, Cancers.

[6]  Lei Zheng,et al.  The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma , 2018, Molecular Cancer.

[7]  K. Odunsi.  Immunotherapy in ovarian cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Weilin Wang,et al.  Pseudogene PDIA3P1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway. , 2017, Cancer letters.

[9]  R. Scharpf,et al.  High grade serous ovarian carcinomas originate in the fallopian tube , 2017, Nature Communications.

[10]  Zhaojian Liu,et al.  miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma , 2017, Cell Death and Differentiation.

[11]  M. Renna,et al.  High mobility group A1 protein modulates autophagy in cancer cells , 2017, Cell Death and Differentiation.

[12]  Ming Sun,et al.  The Pseudogene DUXAP8 Promotes Non-small-cell Lung Cancer Cell Proliferation and Invasion by Epigenetically Silencing EGR1 and RHOB. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Yide Mei,et al.  LncRNA‐MIF, a c‐Myc‐activated long non‐coding RNA, suppresses glycolysis by promoting Fbxw7‐mediated c‐Myc degradation , 2016, EMBO reports.

[14]  L. Resar,et al.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development. , 2016, Current molecular medicine.

[15]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[16]  M. Dinger,et al.  Endogenous microRNA sponges: evidence and controversy , 2016, Nature Reviews Genetics.

[17]  A. Fusco,et al.  HMGA1-pseudogenes and cancer , 2016, Oncotarget.

[18]  R. Cress,et al.  Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer , 2015, Obstetrics and gynecology.

[19]  A. Fusco,et al.  HMGA1-pseudogene expression is induced in human pituitary tumors , 2015, Cell cycle.

[20]  Thomas M. Keane,et al.  The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo , 2015, Cell.

[21]  N. Gellrich,et al.  HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma , 2014, BMC Cancer.

[22]  A. Fusco,et al.  HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs , 2014, Oncotarget.

[23]  R. Verhaak,et al.  The Pan-Cancer Analysis of Pseudogene Expression Reveals Biologically and Clinically Relevant Tumour Subtypes , 2014, Nature Communications.

[24]  Linfu Xie,et al.  miR‐26a inhibits proliferation and motility in bladder cancer by targeting HMGA1 , 2013, FEBS letters.

[25]  L. Poliseno.  Pseudogenes: Newly Discovered Players in Human Cancer , 2012, Science Signaling.

[26]  Peter D. Tonner,et al.  Detecting transcription of ribosomal protein pseudogenes in diverse human tissues from RNA-seq data , 2012, BMC Genomics.

[27]  D. Scholtens,et al.  Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma , 2012, Modern Pathology.

[28]  E. Punch,et al.  Pseudogenes: pseudo-functional or key regulators in health and disease? , 2011, RNA.

[29]  H. Johnsen,et al.  Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers , 2011, PloS one.

[30]  P. Pandolfi,et al.  A coding-independent function of gene and pseudogene mRNAs regulates tumour biology , 2010, Nature.

[31]  Ximing J. Yang,et al.  HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma , 2010, Modern Pathology.

[32]  S. Hammond,et al.  HMGA2, MicroRNAs, and Stem Cell Aging , 2008, Cell.

[33]  W. V. D. Van de Ven,et al.  Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Ras-regulated expression. , 2007, Cancer research.

[34]  I. Screpanti,et al.  High mobility group A1 is a molecular target for MYCN in human neuroblastoma. , 2005, Cancer research.

[35]  G. Viglietto,et al.  HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. , 2003, Carcinogenesis.

[36]  L. Resar,et al.  HMG-I/Y, a New c-Myc Target Gene and Potential Oncogene , 2000, Molecular and Cellular Biology.

[37]  L. Duret,et al.  Nature and structure of human genes that generate retropseudogenes. , 2000, Genome research.

[38]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  N. Takahashi.  Aging , 1992, Cell.

[40]  Lin Zhang,et al.  MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. , 2018, Cancer research.